Key Developments: Cellcura ASA (CELLC.OL)
0.38NOK
16 May 2013
kr-0.02 (-5.00%)
kr0.40
kr0.44
kr0.44
kr0.37
190,000
18,334
kr0.93
kr0.32
Latest Key Developments (Source: Significant Developments)
Cellcura ASA Announces New Share Capital Registration in Connection with Share Issue
Cellcura ASA announced that with reference to the stock exchange announcement of December 18, 2012 regarding the conversion of convertible loans, 18,319,745 new shares were issued through conversion of the loans at a subscription price of NOK 0.46. The share capital was increased by NOK 1,831,974.50. The share capital increase was registered with the Register of Business Enterprises on January 31, 2013. Cellcura ASA's new share capital is NOK 6,576,493.60 divided on 65,764,936 shares each with a nominal value of NOK 0.10. The new shares issued are expected to be delivered immediately to the lenders/subscribers' VPS accounts. The new shares will be tradable on delivery. Full Article
Cellcura ASA Enters Asia with First Sale to IVF Institution in China
Cellcura ASA announced that it steps into Asia with the first sale of its ART Lab solution to Peking University Third Hospital IVF Center, People's Republic of China. The CellCura ART Lab Solution will be immediately operational for routine treatment in the clinic, which is looking to expand its treatment capacity in the next few years, cutting down on ever increasing waiting lists in the region. This first Chinese contract has been developed in partnership with a distributor Guangzhou Haoxin Instrument Co Ltd and their subsidiary Hong Kong Long Sense Development Ltd. The financial details were not disclosed. Full Article
Cellcura ASA Provides Details on Subsequent Offering
Cellcura ASA announced that with reference to the stock exchange announcement of December 14, 2012 regarding the final results of the completed subsequent offering, the issuance of 1,019,600 new shares in the subsequent offering was conducted at a subscription price of NOK 0.46. The share capital was increased by NOK 101,960. The share capital increase was registered with the Register of Business Enterprises on December 31, 2012. Cellcura ASA's new share capital is NOK 4,744,519.10 divided on 47,445,191 shares each with a nominal value of NOK 0.10. The new shares issued in the subsequent offering are expected to be delivered immediately to the subscribers' VPS accounts. The new shares will be tradable on delivery. Full Article
Cellcura ASA's CEO Lars Bredahl Steps Down; Company Appoints Tore Kvam Acting CEO
Cellcura ASA announced that Lars Bredahl and the Board of Directors in the Company have jointly decided, with effect from December 21, 2012, that Mr. Bredahl will step down as Chief Executive Officer (CEO) for the Company due to different views of the future development for the Company. Tore Kvam (Chief Financial Officer) will be acting CEO from December 21, 2012 until new appointment is made. The search for new CEO will start immediately. Full Article
Cellcura ASA Announces Conversion of Convertible Loan
Cellcura ASA announced that it has entered into agreements with convertible loan lenders with regard to conversion of loans they have issued to the Company. The lenders will in total convert loans of NOK 8,427,082.70. The subscription price is NOK 0.46 per share. The share capital of the Company will be NOK 6,576,493.60 divided on 65,764,936 shares, each with a nominal value of NOK 0.10 per share, after the conversion of the loans. The conversion of loans takes place in order to secure necessary financing of the Company. Full Article
Cellcura ASA Comments on Results of Offering and Potential Financing
Cellcura ASA announced with reference to previous announcements related to the process of strengthening the Company's capital base, that at the expiry of the subscription period for the private placement, tranche 2, the Company has not succeeded in raising additional capital for the Company. However, the Company has a dialog with investors in order to establish a convertible loan of between NOK 6 million and NOK 8 million in order to secure operations. The Company's main shareholder Dag Dvergsten AS has confirmed participation in the loan with NOK 2 million, and other main shareholders has confirmed their interest in financing the Company. It is the opinion of the Board that it is likely that the Company may enter into financing agreements within the time frame the Company's liquidity situation allows. The Company has additionally implemented cost reducing activities with effect from the turn of the year. In case CellCura does not succeed to find a solution to the Company's short-term financial requirements, the Company will have to decrease its activity level until a long term financial solution is in place. Alternatively, the Board will consider sale of assets. The newly approved patent for protein free media is expected to have a considerable value. The work for a long-term financial solution will be continuing immediately. Full Article
Cellcura ASA Announces Final Results of Subsequent Offering
Cellcura ASA announced that at the expiry of the subscription period for the subsequent offering, Cellcura had received subscriptions for a total of 1,019,600 new shares. The Board of Directors of CellCura has approved the final allocation of the shares offered in the subsequent offering based on the allocation criteria set out in the prospectus dated November 12, 2012. Payment for the allocated shares falls due on December 19, 2012 in accordance with the payment procedures described in the prospectus. Subject to timely payment, the share capital increase pertaining to the subsequent offering will be registered with the Norwegian register of Business Enterprises on or about December 20, 2012 and that the new shares will be transferred to the VPS accounts of the subscribers and admitted to trading on Oslo Axess on or about December 20, 2012. The new shares may be traded on the Oslo Axess when they have been fully paid, issued and registered in the VPS. Following the issue of the new shares in the subsequent offering, Cellcura's share capital will be NOK 4,744,519.10 divided by 47,445,191 shares, each with a nominal value of NOK 0.10. Full Article
Cellcura ASA Announces Extension of Subscription Period in Private Placement and Last Day for Subscription in Subsequent Offering
Cellcura ASA announced, with reference to the announcement from November 28, 2012 regarding extension of the subscription period in the Company's private placement (tranche two) and the subsequent offering, that the Company has ongoing discussions with potential new investors. Thus, the Company has resolved to extend the subscription period in the private placement up to December 17, 2012 at 16:30 (CET). The subscription period in the ongoing subsequent offering in CellCura expires on December 12, 2012 at 17:30 (CET). Subscription rights that are not used to subscribe for new shares in the subsequent offering before the expiry of the subscription period will be of no value and will lapse without compensation to the holder. In order to subscribe for new shares holders of subscription rights, whether granted or acquired, must submit a correctly completed and signed subscription form to the manager VL Corporate AS. It is expected that payment for subscribed shares will be made on December 19, 2012. Trading in issued shares is expected to commence on or about December 20, 2012. The shares will be delivered through the facilities of the VPS. Full Article
Cellcura ASA Receives Notice of Allowance for Patent in United States, Australia and Europe
Cellcura ASA announced that it has received a Notice of Allowance from the United States Patent and Trademark office (USPTO) for patent application (No. 12/340,475), a Notice of Acceptance from the Commonwealth of Australia Patent Office for (No. 2008345661) and a Notice of Intention to Grant European Patent (No. 08 866 081.6). The patent covers the use of the Company's core intellectual property in assisted conception, offering both fertility clinics and couples seeking to conceive a child, minimized risk together with a standardized and predictable culture system for assisted reproductive technology (ART) treatments. The allowed claims broadly protect these completely defined formulations for all applications in ART. The CellCura PF PROTEIN FREE media formulations can be directly substituted in all procedures for all current protein-containing culture media. In clinical trials, CellCura PF PROTEIN FREE media has demonstrated clinical performance characteristics, equal to or better than current culture systems that contain proteins from either biological or recombinant origin. Full Article
Cellcura ASA Extends Subscription Period for Private Placement
Cellcura ASA announced that with reference to the announcement of November 13, 2012 in respect of the approved prospectus for listing of shares and commencement of the subscription period in the Company's private placement and subsequent offering, Cellcura ASA has resolved to extend the subscription period up to December 12, 2012 at 16:00 Central European Time (CET). It is expected that payment for subscribed shares will be made on December 17, 2012. Trading in issued shares is expected to commence on or about December 20, 2012. The shares will be delivered through the facilities of the VPS. The extension is made in order to provide remaining potential subscribers an opportunity to finalize their internal investment decisions. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
